{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T17:16:22Z","timestamp":1648746982443},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2015,8,15]],"date-time":"2015-08-15T00:00:00Z","timestamp":1439596800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1007\/s12032-015-0677-9","type":"journal-article","created":{"date-parts":[[2015,8,14]],"date-time":"2015-08-14T06:32:33Z","timestamp":1439533953000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prospective clinical study of R-CMD therapy for indolent B cell lymphoma and mantle cell lymphoma from the Hokuriku Hematology Oncology Study Group"],"prefix":"10.1007","volume":"32","author":[{"given":"Tomoyuki","family":"Sakai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasufumi","family":"Masaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nozomi","family":"Otsuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ippei","family":"Sakamaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Kishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayoshi","family":"Miyazono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshimasa","family":"Urasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomi","family":"Satoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuji","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruka","family":"Iwao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Kawanami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miyuki","family":"Miki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshimasa","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masao","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiro","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiro","family":"Okazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanori","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,8,15]]},"reference":[{"key":"677_CR1","doi-asserted-by":"crossref","first-page":"4351","DOI":"10.1182\/blood-2001-12-0269","volume":"100","author":"AM Tsimberidou","year":"2002","unstructured":"Tsimberidou AM, McLaughlin P, Younes A, Rodriguez MA, Hagemeister FB, Sarris A, et al. Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma. Blood. 2002;100:4351\u20137.","journal-title":"Blood"},{"issue":"4 Suppl","key":"677_CR2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1365-2354.1997.tb00321.x","volume":"6","author":"MJ Keating","year":"1997","unstructured":"Keating MJ, McLaughlin P, Cabanillas F. Low-grade non-Hodgkin\u2019s lymphoma-development of a new effective combination regimen (fludarabine, mitoxantrone and dexamethasone; FND). Eur J Cancer Care. 1997;6(4 Suppl):21\u20136.","journal-title":"Eur J Cancer Care"},{"key":"677_CR3","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1200\/JCO.1996.14.4.1262","volume":"14","author":"P McLaughlin","year":"1996","unstructured":"McLaughlin P, Hagemeister FB, Romaguera JE, Sarris AH, Pate O, Younes A, et al. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol. 1996;14:1262\u20138.","journal-title":"J Clin Oncol"},{"key":"677_CR4","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/cncr.21151","volume":"104","author":"AM Tsimberidou","year":"2005","unstructured":"Tsimberidou AM, Younes A, Romaguera J, Hagemeister FB, Rodriguez MA, Feng L, et al. Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen. Cancer. 2005;104:345\u201353.","journal-title":"Cancer"},{"key":"677_CR5","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3109\/10428199909167397","volume":"32","author":"T Robak","year":"1999","unstructured":"Robak T, Gora-Tybor J, Urba\u0144ska-Ry\u015b H, Krykowski E. Combination regimen of 2-chlorodeoxyadenosine (cladribine), mitoxantrone and dexamethasone (CMD) in the treatment of refractory and recurrent low grade non-Hodgkin\u2019s lymphoma. Leuk Lymphoma. 1999;32:359\u201363.","journal-title":"Leuk Lymphoma"},{"key":"677_CR6","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood.V96.1.71","volume":"96","author":"IW Flinn","year":"2000","unstructured":"Flinn IW, Byrd JC, Morrison C, Jamison J, Diehl LF, Murphy T, et al. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood. 2000;96:71\u20135.","journal-title":"Blood"},{"key":"677_CR7","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/S0959-8049(02)00143-0","volume":"38","author":"MJ Rummel","year":"2002","unstructured":"Rummel MJ, Chow KU, Karakas T, J\u00e4ger E, Mezger J, von Gr\u00fcnhagen U, et al. Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin\u2019s lymphoma. Eur J Cancer. 2002;38:1739\u201346.","journal-title":"Eur J Cancer"},{"key":"677_CR8","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1080\/1042819032000159825","volume":"45","author":"T Robak","year":"2004","unstructured":"Robak T, Smolewski P, Urbanska-Rys H, Gora-Tybor J, Blonski JZ, Kasznicki M. Rituximab followed by cladribine in the treatment of heavily pretreated patients with\u00a0indolent\u00a0lymphoid malignancies. Leuk Lymphoma. 2004;45:937\u201344.","journal-title":"Leuk Lymphoma"},{"key":"677_CR9","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1080\/10428190701361216","volume":"48","author":"T Robak","year":"2007","unstructured":"Robak T, Lech-Maranda E, Janus A, Blonski J, Wierzbowska A, Gora-Tybor J. Cladribine combined with cyclophosphamide and mitoxantrone is an active salvage therapy in advanced non-Hodgkin\u2019s lymphoma. Leuk Lymphoma. 2007;48:1092\u2013101.","journal-title":"Leuk Lymphoma"},{"key":"677_CR10","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244\u201353.","journal-title":"J Clin Oncol"},{"key":"677_CR11","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1200\/JCO.2007.12.5070","volume":"26","author":"JW Friedberg","year":"2008","unstructured":"Friedberg JW, Cohen P, Chen L, Robinson KS, Forero-Torres A, La Casce AS, et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin\u2019s lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol. 2008;26:204\u201310.","journal-title":"J Clin Oncol"},{"key":"677_CR12","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/bjh.12695","volume":"164","author":"A Ibatici","year":"2014","unstructured":"Ibatici A, Pica GM, Nati S, Vitolo U, Botto B, Ciochetto C, et al. Safety and efficacy of 90Yttrium-Ibritumomab-Tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study. Br J Haematol. 2014;164:710\u20136.","journal-title":"Br J Haematol"},{"key":"677_CR13","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1349-7006.2008.00999.x","volume":"100","author":"K Tobinai","year":"2009","unstructured":"Tobinai K, Watanabe T, Ogura M, Morishima Y, Hotta T, Ishizawa K, et al. Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma. Cancer Sci. 2009;100:158\u201364.","journal-title":"Cancer Sci"},{"key":"677_CR14","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Gr\u00fcnhagen U, Losem C, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381:1203\u201310.","journal-title":"Lancet"},{"key":"677_CR15","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1002\/cncr.26660","volume":"118","author":"R Sinha","year":"2012","unstructured":"Sinha R, Kaufman JL, Khoury HJ Jr, King N, Shenoy PJ, Lewis C, et al. A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas. Cancer. 2012;118:3538\u201348.","journal-title":"Cancer"},{"key":"677_CR16","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1200\/JCO.2010.32.1844","volume":"29","author":"N Fowler","year":"2011","unstructured":"Fowler N, Kahl BS, Lee P, Matous JV, Cashen AF, Jacobs SA, et al. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study. J Clin Oncol. 2011;29:3389\u201395.","journal-title":"J Clin Oncol"},{"key":"677_CR17","doi-asserted-by":"crossref","unstructured":"Leonard J, Jung S, Johnson J, Bartlett N, Blum K, Cheson B, et al (2012) CALGB 50401: a randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma. In: ASCO meeting abstracts, vol 30, 15 Suppl., p 8000.","DOI":"10.1200\/jco.2012.30.15_suppl.8000"},{"key":"677_CR18","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1200\/JCO.2003.09.047","volume":"21","author":"WS Velasquez","year":"2003","unstructured":"Velasquez WS, Lew D, Grogan TM, Spiridonidis CH, Balcerzak SP, Dakhil SR, et al. Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma: S9501. J Clin Oncol. 2003;21:1996\u20132003.","journal-title":"J Clin Oncol"},{"key":"677_CR19","unstructured":"McLaughlin P, Rodriguez MA, Hagemeister FB, McLaughlin P, Rodriguez MA, Hagemeister FB, et al Stage IV indolent lymphoma: a randomized study of concurrent vs. sequential use of FND chemotherapy (fludarabine, mitoxantrone, dexamethasone) and rituximab monoclonal antibody therapy, with interferon maintenance. In: Proceedings of American Society of Clinical Oncology, 2003, vol 102, p 564, abstract 2269."},{"key":"677_CR20","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/1042819031000139765","volume":"45","author":"R Bordonaro","year":"2004","unstructured":"Bordonaro R, Petralia G, Restuccia N, Todaro AM, Serraino D, Giuffrida D, et al. Fludarabine, mitoxantrone and dexamethasone as front-line therapy in elderly patients affected by newly-diagnosed, low-grade non-Hodgkin\u2019s lymphomas with unfavorable prognostic factors: results of a phase II study. Leuk Lymphoma. 2004;45:93\u2013100.","journal-title":"Leuk Lymphoma"},{"key":"677_CR21","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3324\/haematol.11671","volume":"93","author":"S Montoto","year":"2008","unstructured":"Montoto S, Moreno C, Domingo-Dom\u00e9nech E, Estany C, Oriol A, Alt\u00e9s A, et al. High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma. Haematologica. 2008;93:207\u201314.","journal-title":"Haematologica"},{"key":"677_CR22","doi-asserted-by":"crossref","first-page":"5067","DOI":"10.1002\/cncr.26121","volume":"117","author":"TP Srokowski","year":"2011","unstructured":"Srokowski TP, Liebmann JE, Modiano MR, Cohen GI, Pro B, Romaguera JE, et al. Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: phase 1 study with a dose-expansion cohort. Cancer. 2011;117:5067\u201373.","journal-title":"Cancer"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-015-0677-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-015-0677-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-015-0677-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T05:33:54Z","timestamp":1599456834000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-015-0677-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,15]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["677"],"URL":"https:\/\/doi.org\/10.1007\/s12032-015-0677-9","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,15]]},"article-number":"232"}}